A Phase 3 Study of Ruxolitinib Cream in Children Aged 2-<12 Years with Atopic Dermatitis (TRuE-AD3): 8-Week Analysis
Publication/Presentation Date
Summer 2023
Volume
17
Issue
3
Published In/Presented At
Eichenfield, Lawrence F. MD1; Stein Gold, Linda F. MD, PhD2; Simpson, Eric L. MD, MCR3; Zaenglein, Andrea L. MD4; Armstrong, April W. MD, PhD, MPH5; Tollefson, Megha M. MD6; Soong, Weily MD7; Lee, Lara Wine MD, PhD8; Devani, Alim R. MD9; Forman, Seth B. MD10; Siri, Dareen D. MD11; Angel, Brett MD12; Kallender, Howard PhD12; Li, Qian PhD12; Paller, Amy S. MD13. A Phase 3 Study of Ruxolitinib Cream in Children Aged 2-<12 Years with Atopic Dermatitis (TRuE-AD3): 8-Week Analysis. Journal of Dermatology for Physician Assistants 17(3):, Summer 2023.
Disciplines
Medicine and Health Sciences
Department(s)
Department of Medicine Faculty
Document Type
Article
COinS
